Correspondence 0001193125-24-164446 from CERENOME, INC. (PSTV)
CERENOME, INC.
Date: June 20, 2024 · CIK: 0001095981 · Accession: 0001193125-24-164446
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-280061
Letter
Plus Therapeutics, Inc.
4200 Marathon Blvd., Suite 200
Austin, TX 78756
June 20, 2024
VIA EDGAR
Mr. Tyler Howes
Office of Life Sciences
Division of Corporation Finance
U.S. Securities and Exchange Commission
100 F Street N.E.
Washington, D.C. 20549
Re: Plus Therapeutics, Inc.
Registration Statement on Form S-1
File No. 333-280061
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, the undersigned, on behalf of Plus Therapeutics, Inc. (the “Company”), respectfully requests that the effective date of the Registration Statement on Form S-1 referred to above be accelerated so that it will become effective at 5:00 P.M. Eastern Time on June 24, 2024, or as soon as practicable thereafter, or at such other time as the Company may orally request by telephone.
Please contact William Intner of Hogan Lovells US LLP, counsel to the Company, at (410) 659-2778, to provide notice of effectiveness, or if you have any questions or require additional information regarding this matter. Thank you for your assistance and cooperation in this matter.
Very truly yours,
PLUS THERAPEUTICS, INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP Plus Therapeutics, Inc. 4200 Marathon Blvd., Suite 200 Austin, TX 78756 June 20, 2024 VIA EDGAR Mr. Tyler Howes Office of Life Sciences Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 Re: Plus Therapeutics, Inc. Registration Statement on Form S-1 File No. 333-280061 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, the undersigned, on behalf of Plus Therapeutics, Inc. (the “Company”), respectfully requests that the effective date of the Registration Statement on Form S-1 referred to above be accelerated so that it will become effective at 5:00 P.M. Eastern Time on June 24, 2024, or as soon as practicable thereafter, or at such other time as the Company may orally request by telephone. Please contact William Intner of Hogan Lovells US LLP, counsel to the Company, at (410) 659-2778, to provide notice of effectiveness, or if you have any questions or require additional information regarding this matter. Thank you for your assistance and cooperation in this matter. Very truly yours, PLUS THERAPEUTICS, INC. By: /s/ Marc H. Hedrick March H. Hedrick President and Chief Executive Officer cc: Andrew Sims, Plus Therapeutics, Inc. Kara Davis, Plus Therapeutics, Inc William Intner, Hogan Lovells US LLP Andrew L. Strong, Hogan Lovells US LLP